Show simple item record

dc.contributor.authorCano Cortes, María Victoria 
dc.contributor.authorNavarro Marchal, Saul Abenhamar 
dc.contributor.authorRuiz-Blas, María Paz
dc.contributor.authorDíaz Mochón, Juan José 
dc.contributor.authorMarchal Corrales, Juan Antonio 
dc.contributor.authorSánchez Martín, Rosario María 
dc.date.accessioned2019-12-18T13:31:05Z
dc.date.available2019-12-18T13:31:05Z
dc.date.issued2020
dc.identifier.citationCano-Cortes M.V., et al., A versatile theranostic nanodevice based on an orthogonal bioconjugation strategy for efficient targeted treatment and monitoring .... Nanomedicine: NBM 2020;24:1-11, [https://doi.org/10.1016/j.nano.2019.102120]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/58397
dc.descriptionSupplementary data to this article can be found online at https://doi.org/10.1016/j.nano.2019.102120.es_ES
dc.description.abstractA novel chemical-based orthogonal bioconjugation strategy to produce tri-functionalized nanoparticles (NPs) an chemotherapy drug, doxorubicin (DOX), a near-infrared cyanine dye (Cy7) and CRGDK homing peptide, a peptide specifically binds to neuropilin-1 (Nrp-1) overexpressed on triple negative breast cancer (TNBC) cells, has been validated. These theranostic NPs have been evaluated in vitro and in vivo using an orthotopic xenotransplant mouse model using TNBC cells. In vitro assays show that theranostic NPs improve the therapeutic index in comparison with free DOX. Remarkably, in vivo studies showed preferred location of theranostic NPs in the tumor area reducing the volume at the same level than free DOX while presenting lower side effects. This multifunctionalized theranostic nanodevice based on orthogonal conjugation strategies could be a good candidate for the treatment and monitoring of Nrp-1 overexpressing tumors. Moreover, this versatile nanodevice can be easily adapted to treat and monitor different cancer types by adapting the conjugation strategy.es_ES
dc.description.sponsorshipMinistry of Economy and Competitiveness (MINECO, National Programme for Research Aimed at the Challenges of Society, project reference BIO2016-80519-R&FEDER funds, grant number MAT2015-62644.C2.2.R)es_ES
dc.description.sponsorshipMinisterio de Ciencia, Innovación y Universidades grant number RTI2018-101309-B-C2 (FEDER Funds)
dc.description.sponsorshipHealth Institute Carlos III (ISCIII) (Projects of technological development in health - ref DTS18/00121)
dc.description.sponsorshipUniversity of Granada – PLAN OF RESEARCH AND TRANSFER 2016 –PSETC- PSE/16/003)
dc.description.sponsorshipProject MAT2015-62644.C2.2.R
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectPolymeric nanoparticleses_ES
dc.subjectOrthogonal chemistryes_ES
dc.subjectCovalent conjugationes_ES
dc.subjectDoxorubicines_ES
dc.subjectCRGDK targetinges_ES
dc.subjectMultifunctional theranostic nanodevicees_ES
dc.titleA versatile theranostic nanodevice based on an orthogonal bioconjugation strategy for efficient targeted treatment and monitoring of triple negative breast canceres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.nano.2019.102120


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España